Mononuclear cells express enzymes involved in the NO/cyclic guanosine monophosphate (cGMP) generating system, as well as PDE5. The objective of the study was to determine the effect of sildenafil citrate administration on the level of proteins involved in the NO/cGMP generating system in mononuclear cells from patients with ED. Twenty-one patients with ED (International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) 17.9±0.8) were enrolled and 100 mg sildenafil citrate on-demand was administered during 12 weeks. All patients showed cardiovascular risk factors. After sildenafil citrate administration, IIEF-EFD score was improved (26 ± 1.2 Po0.05). In the mononuclear cells, the protein level of endothelial NO synthase (eNOS) was higher after sildenafil citrate treatment. It was accompanied by reduction in the circulating plasma levels of both high-sensitive C-reactive protein and soluble intercellular adhesive molecule-1. The protein level of soluble guanylate cyclase and PDE5 did not change in the mononuclear cells after sildenafil citrate treatment. However, in the mononuclear cells exogenous NO induced a higher cGMP production after 12-weeks sildenafil citrate administration. In conclusion, in mononuclear cells from patients with ED sildenafil citrate administration increased the level of eNOS protein and increased cGMP production in response to NO. Moreover, sildenafil citrate administration reduced the plasma circulating levels of two biomarkers associated with inflammation.
Introduction
Medical management of ED was re-defined after the knowledge that the signaling system of NO-cyclic guanosine monophosphate (cGMP) is pivotal for the arterial dilatation and venous occlusion is necessary to maintain and support an erection. NO is known to activate both the a 1 -and b 1 -subunits of the soluble guanylate cyclase (sGC) resulting in the enhanced formation of cGMP. 1, 2 In the human cavernous tissue, cGMP is catabolized by PDE5. 3 First purified from rat lung, 4 PDE5 has also been identified in many species and a wide variety of tissues. 5, 6 A great physiological protein level of PDE5 in penile organ has been found, being 10-to 100-fold more abundant in corpus cavernosum than in other nonreproductive tissues. 7 Recent studies have shown that in mononuclear cells the level of proteins involved in the NO-cGMP system was altered in patients with ED. 8 Indeed, in mononuclear cells from patients with ED of vascular origin the protein level of the endothelial NO synthase (eNOS), an enzyme that generates NO also present in the endothelium, was reduced while both the sGCb 1 -subunit and PDE5 were higher than those found in mononuclear cells from patients without ED. 8 PDE5 inhibitors are a class of vasoactive drugs developed for ED treatment. 9, 10 The first approved compound to inhibit PDE5 was sildenafil citrate, which has shown efficacy and safety in clinical trials for ED. [11] [12] [13] Sildenafil acts through the increase of the relaxing action of NO on corpus cavernosal smooth muscle cells by preventing cGMP enzymatic hydrolysis. Thus, the therapeutic use of sildenafil has been closely linked to the NO/cGMP system. In this regard, currently marketed drugs for the treatment of ED such as sildenafil citrate have beneficial effects in other cardiovascular conditions, including congestive heart failure, pulmonary hypertension as well as in the setting of endothelial dysfunction. 14, 15 However, to our knowledge, the effect of PDE5 inhibition with sildenafil citrate on the NO/cGMP generating system in mononuclear cells from patients with ED has not yet been explored. In this study, we have shown that sildenafil citrate treatment of patients with ED of vascular origin increased the protein level of eNOS in their mononuclear cells without changes in the protein level of both sGCb 1 -subunit and PDE5.
Materials and methods

Study protocol
Twenty-one patients (65±10-years old) in a heterosexual relationship for at least a year were enrolled in the study. All included patients showed alterations to prostaglandin E1, a vasodilator, during the Echo-Doppler examination (Toshiba kit model USDI-770A, 7 Mhz transductor). In this regard, at inclusion the Echo-Doppler study showed, after intracavernosal injection of prostaglandin E1 (20 mg), a reduced vasodilatation of the cavernosal arteries (up to 75% reduction from normal value). Moreover, an increased systolic velocity up 15% from normal values was observed (mean value 25 ± 3.8 cm s À1 ). In addition, the end-diastolic velocity used to detect veno-occlusive dysfunction was within the normal range (4.0 ± 0.5 cm s À1 ). Patients also showed ED status related to the International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) 16 (score417 and o21 representing an ED status of mild-to-moderate) and a history of at least one of the following cardiovascular risk factors: type-II diabetes mellitus, essential hypertension and elevated plasma cholesterol levels patients (4200 mg per 100 ml). Type II diabetes mellitus was established to be at least 1 year in duration and fulfill the criteria of the Expert Committee on the diagnosis and classification of diabetes. At inclusion, all the patients had pharmacologically controlled their cardiovascular risk factors by using statins, b-blockers, angiotensin-I converting enzyme inhibitors, angiotensin-II receptor blockers, antidiabetic drugs and antiplatelet agents for at least 6 months before they were included. The cardiovascular treatment was not changed during the followup. The included patients declared that they had not taken PDE5 inhibitors at any time before. Patients were excluded from the study based on the exclusion criteria typically used in studies with PDE5 inhibitors for ED treatment. 17 Patients received sildenafil citrate (Viagra) 100 mg on-demand during 12 weeks. Concomitant use of other therapies for ED was not allowed. At the beginning of sildenafil citrate administration and at the end of the 12 weeks of sildenafil citrate administration, peripheral blood samples were obtained for plasma and mononuclear cell isolation. Free testosterone levels were also determined both at inclusion and at the end of sildenafil citrate administration by routine laboratory tests performed in a central laboratory using standard equipment and certified methods. Blood samples were always collected between 2 and 3 days after the last dose of sildenafil citrate.
Mononuclear cells were isolated by Ficoll-Hypaque centrifugation (#1692254; MP Biomedicals, Inc., France). The mononuclear cell layer was collected from the interface and to remove the contaminating platelets it was washed twice in RPMI medium containing 0.025% bovine serum albumin. Mononuclear cells were then resuspended and divided into different aliquots to perform the in vitro incubation with and without sodium nitroprusside (SNP). A number of the isolated mononuclear cells were immediately frozen at À80 1C until use for molecular determinations.
All subjects gave fully informed consent and the study was approved by the local ethic committee. The study was blind for the researchers that determined the molecular parameters and analyzed the results.
Outcome measures for ED classification were based on the IIEF-EFD scores defined by Cappelleri et al. 16 Molecular determinations were based on electrophoretic analysis using western blot techniques. Measurements of inflammatory-related parameters were based on enzyme-linked immunosorbent assays.
Determination of the protein levels of eNOS, sGCb 1 -subunit and PDE5 As described earlier, the protein levels of eNOS, sGCb 1 -subunit and PDE5 were analyzed by western blotting. 18, 19 In brief, mononuclear cells were resuspended and solubilized in Laemmli buffer containing 2-mercaptoethanol. 20 The proteins obtained were separated in denaturing SDS 10% polyacrylamide gels. Equal amounts of proteins (20 mg per lane) estimated by bicinchoninic acid reagent (Pierce Rockford, IL, USA) were loaded. Western blot analysis was performed with a monoclonal antibody against eNOS (#N30020; 1:1500 Transduction Laboratories, San Diego, CA, USA), sGC b 1 -subunit (#210-786; 1:1500; Alexis laboratories, San Diego, CA, USA) or PDE5 (#524583; 1:1500 Calbiochem, La Jolla, CA, USA). The constitutive protein b-actin was also determined by using a specific monoclonal Sildenafil citrate and mononuclear cells J García-Cardoso et al antibody (#A5441; 1:2500; Sigma Chemical Co, St Louis, USA). Blots were incubated with the first antibody against eNOS, sGCb 1 -subunit, PDE5 or b-actin for 1 h at room temperature and, after extensive washing, with the second antibody (horseradish peroxidase-conjugated IgG antibody) at 1:2500 dilution for another hour. Specific eNOS, sGCb 1 -subunit, PDE5 and b-actin proteins were detected by enhanced chemoluminescence (Amersham Corp) and evaluated by densitometry (Molecular Dynamics). Prestained protein markers (Sigma) were used for molecular mass determinations.
Determination of sGC activity
The 5 Â 10 6 mononuclear cells per tube were incubated at 37 1C in RPMI medium containing 0.025% bovine serum albumin for 15 min. To investigate the functional activity of sGC, mononuclear cells were incubated in the presence and in the absence of an NO donor, SNP (10 À5 mol l À1 ), for 15 min. Afterwards, mononuclear cells were lysed in 1 mol l À1 HCl in ethanol. The homogenates were centrifuged (1200 g, 15 min at 4 1C) and the supernatants were then recovered and dried by speedvaac. cGMP was measured in acetylated samples with a kit from Amersham International as reported. 21 Determination of soluble intercellular adhesion molecule-1 and high-sensitive C-reactive protein Soluble intercellular adhesion molecule-1 (sICAM-1) and high-sensitive C-reactive protein (hs-CRP) levels were measured in the systemic plasma of patients with ED by an enzyme-linked immunosorbent assay kit. The enzyme-linked immunosorbent assay kits were purchased from Bender MedSystems (Vienna, Austria). The sensitivity of the sICAM-1 and hsCRP was 2.17 ng ml À1 and 3 pg ml À1 , respectively. As reported, 22 each sample was measured by duplicate and the arithmetic average was used for data analysis.
Statistical analysis
Results are expressed as mean ± standard deviation. To determine the statistical significance before and after the sildenafil citrate treatment, the Wilcoxon's test was used. The differences between the patients who had taken one or two doses of sildenafil citrate were analyzed using the Mann-Whitney test. A P-valueo0.05 was considered statistically significant. Spearman's correlation analysis was used to determine associations between the level of the different experimental biomarkers and the clinical parameters. A P-value o0.05 was considered statistically significant.
Results
Patients
The clinical data of the 21 included patients are shown in Table 1 . At inclusion, the mean baseline IIEF-EFD score was 17.9±0.8; 12 weeks after sildenafil citrate administration the IIEF-EFD score was significantly improved (26.2 ± 1.2 Po0.05). Free testosterone levels were within normal ranges and no differences were found after 12-week sildenafil citrate administration (before sildenafil citrate: 18.3 ± 1.5; after sildenafil citrate: 20.1 ± 2.1 pg ml À1 ).
eNOS, sGCb 1 -subunit and PDE5 in mononuclear cells In mononuclear cells from ED patients the level of eNOS protein was higher after 12-weeks sildenafil citrate administration (Figure1; Table 2 ). In mononuclear cells from ED patients, sildenafil citrate administration did not change the protein level of either the sGCb 1 -subunit or PDE5 ( Figure 1 ; Table 2 ). There was no statistical correlation between the protein levels of eNOS, sGCb 1 -subunit and PDE5 with age, body mass index, glycosilated hemoglobin levels and cholesterol levels (Table 3) .
cGMP levels in mononuclear cells and hs-CRP and sICAM-1 in the plasma Basal cGMP levels in mononuclear cells from patients with ED were not significantly modified 12 weeks after sildenafil citrate administration (Table 4) . Before sildenafil citrate administration, stimulation of mononuclear cells with the exogenous NO donor, SNP, (10 À5 mol l À1 ) significantly increased cGMP levels (Table 4) . After sildenafil citrate administration, the increase in the cGMP levels elicited by 10 À5 mol l À1 SNP on the mononuclear cells was greater than those observed before sildenafil citrate (Table 4) .
Sildenafil citrate administration significatively reduced sICAM-1 plasma levels in the patients with ED (Figure 2a) . In this regard, the mean value of Sildenafil citrate and mononuclear cells J García-Cardoso et al sICAM-1 in plasma was 456.42 ± 71.6 ng ml À1 at inclusion and 373.9 ± 58.4 ng ml À1 12 weeks after sildenafil citrate treatment (Po0.05). Moreover, hs-CRP plasma levels were also decreased 12 weeks after sildenafil citrate administration (Figure 2b) . Indeed, at inclusion hs-CRP plasma levels were 0.43±0.3 mg l À1 and 12 weeks after sildenafil citrate 0.21 ± 0.1 mg l À1 (Po0.05). At inclusion there was no statistical correlation between sICAM-1 and hs-CRP plasma levels with the clinical data (Table 3) . Moreover, there was no correlation between the level of eNOS protein in mononuclear cells and the plasma level of either sICAM-1 or hs-CRP (Table 5) .
Effect of one and two doses 100 mg sildenafil citrate by week A more detailed examination of the clinical data of the included patients with ED showed that 12 of them had taken two separate doses of 100 mg sildenafil citrate per week whereas the remaining 9 patients had taken only one dose of sildenafil citrate (100 mg) weekly. After 12-weeks sildenafil citrate 
Discussion
The present work shows for the first time the effect of the therapy with the PDE5 inhibitor sildenafil citrate on the main proteins involved in the NO/cGMP signaling system in mononuclear cells from patients with ED. Twelve weeks after sildenafil citrate administration the protein level of eNOS was higher in the mononuclear cells without changes in the protein levels of either sGCb 1 -subunit or PDE5. Moreover, sildenafil citrate administration enhanced the ability of mononuclear cells to produce cGMP in response to the exogenous NO donor SNP. In a previous work, the level of eNOS protein was found to be reduced in mononuclear cells from patients with ED of vascular origin. 8 In this work, 12 weeks after sildenafil citrate administration, mononuclear cells from vascular patients with ED showed a significant increase in the level of eNOS protein. Accordingly to our results, Das et al. 23 also showed an enhanced level of eNOS protein in sildenafilincubated mouse ventricular myocytes that also contain PDE5.However, as occurs in this study, the molecular mechanisms responsible for the increased level of eNOS protein related to sildenafil citrate administration remained to be established. 
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Several studies, particularly in vitro studies, have shown that inflammation is involved in a reduced level of eNOS protein in both endothelium and leukocytes. 24, 25 The ED patients included here showed cardiovascular risk factors, which may favor a pro-inflammatory state. In our patients, the circulating plasma levels of two biomarkers associated with inflammation and endothelial dysfunction, namely, sICAM-1 and hs-CRP were reduced after sildenafil citrate administration, which might suggest an anti-inflammatory effect of sildenafil citrate in patients with ED of vascular origin. Accordingly, a recent study from Rodriguez-Iturbe et al. 26 has also shown that sildenafil citrate administration reduced inflammation in rats with 5/6 nephrectomy. Results from other authors also showed significant reduction in the circulating plasma levels of hs-CRP and interleukin-6 in diabetic patients after sildenafil treatment, suggesting improvement of their inflammatory state. 27 In contrast, Burnett et al. 28 did not observe differences in the inflammatory state of ED patients after sildenafil treatment, although substantial vascular benefits were observed. Therefore, further studies are needed to determine other inflammatory-associated biomarkers to assess the possible beneficial effects of sildenafil citrate on inflammation. However, as speculation, the reduction in the possible pro-inflammatory situation and/or the reduction in both sICAM-1 and hs-CRP levels by sildenafil citrate administration in patients with ED of vascular origin might contribute to protect the level of eNOS protein in the mononuclear cells from ED patients. However, we did not observe any correlation between the level of eNOS protein in mononuclear cells and the plasma levels of either sICAM-1 or hs-CRP, which may suggest that at least the plasma levels of these two pro-inflammatory biomarkers were not associated with the level of eNOS protein in mononuclear cells from patients with ED.
It is difficult to assess the molecular mechanism by which the level of eNOS protein was greater in mononuclear cells after sildenafil citrate administration. It has been reported that testosterone influences both the level of eNOS protein and erectile functionality. 29 Moreover, Carosa et al. 30 have reported increased testosterone plasma levels after sildenafil citrate treatment. In this study, no changes in free testosterone plasma levels were observed after sildenafil treatment, which diminished the involvement of testosterone in the findings reported here. Accordingly, Koulikov D et al. 31 also failed to observe the changes in free testosterone levels after sildenafil citrate treatment. We cannot exclude the possibility that the higher level of eNOS protein in mononuclear cells after sildenafil citrate administration may be the reflection of a better endothelial functionality related to sildenafil citrate administration. In this regard, Musicki et al. 32 showed that long-term administration of sildenafil citrate increased eNOS function in the endothelium from aging rats, which may be associated with improvement of the endothelial functionality.
This study further analyzed whether the use of sildenafil citrate may modify the protein level of sGCb 1 -subunit and PDE5 in the mononuclear cells from patients with ED. The level of either of them was not modified after sildenafil citrate administration. Moreover, although the level of eNOS protein was increased after 12-weeks sildenafil citrate administration, the basal cGMP levels were not different before and after sildenafil citrate. This may be explained by the fact that the baseline production of NO by eNOS protein is not enough to be reflected in significant cGMP increase in the mononuclear cells and, therefore, an exogenous stimulus could be needed. A similar effect seems to occur in the corpus cavernosum in which only when a man is sexually stimulated either physically or psychologically, enough amount of NO is released from noncholinergic, non-adrenergic neurons in the penis as well as from endothelial cells to stimulate cGMP production and to induce dilatation of the penis arteries.
The fact that after 12-weeks sildenafil citrate administration the exogenous NO donor, SNP, was able to produce higher cGMP accumulation in mononuclear cells than before sildenafil citrate under circumstances in which sGC and PDE5 protein levels were not modified and may be related to at least a partial inhibition of PDE5 by sildenafil citrate and/or even by metabolites related to sildenafil citrate, which they have also shown to be able to inhibit PDE5. 33, 34 The potential beneficial effects of PDE5 inhibitors in the pulmonary vasculature and in other systems have led to examination of alternative dosing regimens. 35 On the design of this study, patients took sildenafil citrate on-demand. The analysis of the dose regimen followed for the included patients showed that 12 of them took only one 100 mg sildenafil citrate weekly whereas the remaining 9 patients took 100 mg sildenafil citrate twice per week in different days. However, the level of the proteins involved in the NO/cGMP signaling system was not different between the mononuclear cells from patients with ED who had taken one or two sildenafil citrate doses by week. In this regard, different studies have suggested that once-daily dosing of PDE5 inhibitors benefit patients with ED more than on-demand dosing treatment. 36, 37 However, this is not a consistent finding as other studies have shown that on-demand dosing could have no greater clinical benefits than once-daily dosing. 38, 39 As an example, Zumbe et al. 17 showed a comparable efficacy of once-daily dose of PDE5 inhibitors with on-demand on erectile function. However, in a recent clinical study Montorsi et al. 40 proposed that on-demand vardenafil treatment is the best option for the treatment of ED in men after bilateral Sildenafil citrate and mononuclear cells J García-Cardoso et al nerve-sparing radical prostatectomy with respect to daily administration. Similar results were also recently obtained by Vignozzi et al. 41 in a rat experimental model of penile hypoxia showing that PDE5 inhibitors treatment should be started as soon as possible. This study only compared the effect of one and two sildenafil citrate doses on the NO/cGMP system in mononuclear cells, so we cannot rule out the possibility that the use of sildenafil citrate on a daily basis may exerts additional effects on the levels of the proteins involved in the NO/cGMP system in mononuclear cells, which should be further studied.
Study considerations and limitations
Several considerations about this study should be raised. First, a limitation of this study is that the functional consequence of the sildenafil citrate treatment on the enhanced eNOS protein level and NO-stimulated cGMP level in the mononuclear cells was not analyzed. NO prevents leukocyte adhesion to the vascular wall. 42, 43 It is particularly important in the setting of both atherosclerosis and acute coronary syndromes as it is well known that inhibition of leukocytes reduced the size of myocardial damage. 44, 45 In this regard, in experimental animals PDE5 inhibitors, including sildenafil citrate, have shown a significant efficiency to decrease the infarct size after ischemia-reperfusion and this has been mainly attributed to modification of ionic mitochondrial channels although other mechanisms may be involved. 46 Therefore, as speculation, the higher level of eNOS protein and particularly the greater NO-induced cGMP levels elicited after sildenafil citrate therapy might reduce leukocyte activation associated with cardiovascular diseases. 47 Accordingly with this hypothesis, Santos et al. 48 have shown that sildenafil reduced leukocyte adhesion and infiltration to post-capillary vascular endothelium related to indomethacin-induced gastropathy in rats.
Although it would have been desirable to include a placebo group of patients who had taken the same cardiovascular therapy as those treated with sildenafil citrate, it is important to remark that the included ED patients have been treated for at least 6 months before with different cardiovascular drugs and that during the study period, the cardiovascular medication that the patients were previously taking was not changed. The only drug that was added to the ongoing treatment was sildenafil citrate. Therefore, it is a reasonable interpretation that the observed results were due to the addition of sildenafil citrate to the treatment. However, as sildenafil citrate was added to the patients treatment, it may be that the observed effects of sildenafil citrate administration on the level of eNOS protein and NO-stimulated cGMP production in mononuclear cells and even the reduction of shCRP and sICAM-1 could not be only attributed to the PDE5 inhibitor by itself. Therefore, we cannot rule out the possibility that the mentioned effect of sildenafil citrate may be related to its combination with the cardiovascular pharmacological therapy that the patients had taken when sildenafil citrate was added. In this regard, clinical pharmacokinetic data have identified the hepatic formation of circulating active sildenafil citrate metabolites such as UK-103.320, which is a product of sildenafil citrate N-demethylation, and UK-150.564. In addition, other active metabolites from sildenafil citrate have been identified. 33 Therefore, we cannot exclude the possibility that some of the effects of sildenafil citrate that we observed in the mononuclear cells after sildenafil citrate administration could be related to the presence of these metabolites.
It should be also considered that the changes could not be exclusively related to the mononuclear cells themselves as the endothelial progenitor cell subpopulation with that fraction may also contribute to the observed changes. In this regard, Foresta et al. 49 have described that after PDE5 inhibitors administration the number of circulating endothelial progenitor cells in patients with ED was increased. These endothelial progenitor cells have been suggested to have a relevant role in the neovascularization process and endothelial remodelation. Then, further studies are needed to examine the involvement of endothelial progenitor cells in the effects of sildenafil citrate administration on the NO/cGMP system attributed here to mononuclear cells.
Finally, it is reasonable to think that the small cohort of study participants makes it difficult to accurately obtain results about the effect of sildenafil treatment on molecular and functional parameters. Therefore, further studies with larger number of participants are necessary for better understanding of PDE5 inhibitors effects on the NO/cGMP generating system.
Conclusion
For the first time we have shown effects on sildenafil citrate therapy on the NO/cGMP system in mononuclear cells of patients with ED. Moreover, sildenafil citrate treatment reduced the plasma levels of two pro-inflammatory systemic biomarkers, that is hs-CRP and sICAM-1. Overall, these results may provide new molecular basis to continue exploring new therapeutic applications of sildenafil and other clinically approved PDE5 inhibitors.
